Cargando…
GDF‐15 in solid vs non‐solid treatment‐naïve malignancies
AIM: GDF‐15 is an established cardiovascular risk marker but is equally implicated in tumour biology. Elevated levels of GDF‐15 have indeed been observed in distinct tumour entities. This study aimed to explore the relation of GDF‐15 to other cardiac biomarkers and the general association of GDF‐15...
Autores principales: | Arfsten, Henrike, Cho, Anna, Freitag, Claudia, Raderer, Markus, Goliasch, Georg, Bartko, Philipp E., Wurm, Raphael, Strunk, Guido, Gisslinger, Heinz, Marosi, Christine, Kornek, Gabriela, Zielinski, Christoph, Hülsmann, Martin, Pavo, Noemi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899906/ https://www.ncbi.nlm.nih.gov/pubmed/31463975 http://dx.doi.org/10.1111/eci.13168 |
Ejemplares similares
-
The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients
por: Pavo, Noemi, et al.
Publicado: (2019) -
Increased resting heart rate and prognosis in treatment‐naïve unselected cancer patients: results from a prospective observational study
por: Anker, Markus S., et al.
Publicado: (2020) -
The inflammation‐based modified Glasgow prognostic score is associated with survival in stable heart failure patients
por: Cho, Anna, et al.
Publicado: (2020) -
Inflammation-Based Scores as a Common Tool for Prognostic Assessment in Heart Failure or Cancer
por: Arfsten, Henrike, et al.
Publicado: (2021) -
Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF
por: Prausmüller, Suriya, et al.
Publicado: (2020)